
Otsuka’s Sibeprenlimab Demonstrates Meaningful Outcomes in Phase III Study for Immunoglobulin A Nephropathy
Key takeaways Promising interim results support APRIL inhibition as a viable IgAN strategy: Sibeprenlimab achieved a 51.2% reduction in proteinuria at 9 months, marking a strong signal of efficacy for this investigational biologic. Strong operational …